<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726956</url>
  </required_header>
  <id_info>
    <org_study_id>SHLTQC-3</org_study_id>
    <nct_id>NCT04726956</nct_id>
  </id_info>
  <brief_title>A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC</brief_title>
  <official_title>A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of Pancreatic Ductal Adenocarcinoma：A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clarify the diagnostic significance of AKR1B10 in patients&#xD;
      with pancreatic ductal adenocarcinoma, and to combine with CA19-9 to improve the diagnosis&#xD;
      rate of pancreatic ductal adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the value of CA199 AND AKR1B10 before surgery</measure>
    <time_frame>1 week</time_frame>
    <description>Carbohydrate antigen 19-9 (CA19-9) is the conventional biomarker used to assessing disease progression in PDAC patients，AKR1B10 may be a potential tumor biomarker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the value of CA199 AND AKR1B10 on the first day after surgery</measure>
    <time_frame>1 week</time_frame>
    <description>Carbohydrate antigen 19-9 (CA19-9) is the conventional biomarker used to assessing disease progression in PDAC patients，AKR1B10 may be a potential tumor biomarker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the value of CA199 AND AKR1B10 on the third day after surgery</measure>
    <time_frame>1 week</time_frame>
    <description>Carbohydrate antigen 19-9 (CA19-9) is the conventional biomarker used to assessing disease progression in PDAC patients，AKR1B10 may be a potential tumor biomarker.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>case cohort</arm_group_label>
    <description>Pancreatic ductal adenocarcinoma patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control cohort</arm_group_label>
    <description>healthy control person</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population included in the case group was patients with clinically and pathologically&#xD;
        clear pancreatic ductal adenocarcinoma, and the population included in the control group&#xD;
        was a healthy population without any benign or malignant diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent form voluntarily;&#xD;
&#xD;
          2. Experimental group: Patients with pancreatic ductal adenocarcinoma found by&#xD;
             preoperative imaging and after surgical resection;&#xD;
&#xD;
          3. Control group: healthy people of similar age without any benign or malignant diseases;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Case group:&#xD;
&#xD;
          1. Use neoadjuvant chemotherapy before surgery;&#xD;
&#xD;
          2. Consider pancreatic MT before surgery, and postoperative pathology for patients with&#xD;
             non-pancreatic ductal adenocarcinoma;&#xD;
&#xD;
          3. Second surgery; 2. Control group:&#xD;
&#xD;
        1) The tumor index detection is abnormal, and it is still abnormal after re-examination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Lin Zhong</investigator_full_name>
    <investigator_title>Director of Hepatobiliary and Pancreatic Surgery</investigator_title>
  </responsible_party>
  <keyword>pancreatic ductal adenocarcinoma</keyword>
  <keyword>CA199</keyword>
  <keyword>AKR1B10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

